Skip to main content

Table 1 Patient characteristics first hospitalized for AMI with and without DPP-4 inhibitor

From: The impact of DPP-4 inhibitors on long-term survival among diabetic patients after first acute myocardial infarction

Characteristics Control group (N = 2672) DPP-4 inhibitor group (N = 2672) P value
Gender
 Female 1098 (41.09%) 1098 (41.09%) 1
 Male 1574 (58.91%) 1574 (58.91%)  
Age
 Age <65 1064 (39.82%) 1059 (39.63%) 0.8468
 65 ≤ age < 75 707 (26.46%) 725 (27.13%)  
 Age ≥75 901 (33.72%) 888 (33.23%)  
Comorbidities
 Hypertension 2016 (75.45%) 2005 (75.04%) 0.7274
 Dyslipidemia 1996 (74.7%) 1996 (74.7%) 1
 Peripheral vascular disease 144 (5.39%) 144 (5.39%) 1
 Heart failure 971 (36.34%) 994 (37.2%) 0.5141
 End stage renal disease 187 (7%) 187 (7%) 1
 COPD 231 (8.65%) 234 (8.76%) 0.8842
 Cerebrovascular accident 789 (29.53%) 796 (29.79%) 0.8339
Operations
 Percutaneous coronary intervention 1699 (63.59%) 1699 (63.59%) 1
 Coronary artery bypass graft 260 (9.73%) 297 (11.12%) 0.0976
 IABP 240 (8.98%) 248 (9.28%) 0.704
Medication
 Aspirin 2330 (87.2%) 2440 (91.32%) <0.0001
 Clopidogrel 2350 (87.95%) 2454 (91.84%) <0.0001
 Any anti-platelet drug 2513 (94.05%) 2596 (97.16%) <0.0001
 ACEI or ARB 1743 (65.23%) 2007 (75.11%) <0.0001
 Statin 1616 (60.48%) 1780 (66.62%) <0.0001
 β-Blocker 1587 (59.39%) 1884 (70.51%) <0.0001
 CCB 980 (36.68%) 1145 (42.85%) <0.0001
 Heparin or low molecular weight heparin 2174 (81.36%) 2266 (84.81%) 0.0008
 Spironolactone 468 (17.51%) 615 (23.02%) <0.0001
 Nitrate 2245 (84.02%) 2366 (88.55%) <0.0001
 Nicorandil 284 (10.63%) 401 (15.01%) <0.0001
 α-Glucosidase 197 (7.37%) 602 (22.53%) <0.0001
 Glinides 311 (11.64%) 644 (24.1%) <0.0001
 Metformin 781 (29.23%) 1168 (43.71%) <0.0001
 Sulfonylureas 778 (29.12%) 1420 (53.14%) <0.0001
  1. ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker, CCB calcium channel blocker, COPD chronic obstructive pulmonary disease